Company profile for Pulmocide

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Pulmocide is a unique biopharmaceutical company with a mission to treat common acute and chronic respiratory tract infections associated with serious complications and devastating effects on patients’ quality of life. Unlike currently available treatments for fungal infections in the lung, our innovative approach to drug development provides targeted delivery to the lung so that infections can be treated with minimal unwant...
Pulmocide is a unique biopharmaceutical company with a mission to treat common acute and chronic respiratory tract infections associated with serious complications and devastating effects on patients’ quality of life. Unlike currently available treatments for fungal infections in the lung, our innovative approach to drug development provides targeted delivery to the lung so that infections can be treated with minimal unwanted systemic effects.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
United Kingdom
Address
Address
44 Southampton Buildings London WC2A 1AP
Telephone
Telephone
+44 203 763 9484
Linkedin
Linkedin
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Tides Asia

Tides Asia

Not Confirmed

envelop Contact Supplier

Tides Asia

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.globenewswire.com/news-release/2025/01/10/3007635/0/en/Pulmocide-Announces-Presentation-at-43rd-Annual-J-P-Morgan-Healthcare-Conference.html

GLOBENEWSWIRE
10 Jan 2025

https://www.globenewswire.com/news-release/2024/04/15/2862691/0/en/Pulmocide-Announces-Successful-Results-from-the-OPERA-S-Study-a-Phase-2-Safety-Study-with-Inhaled-Opelconazole.html

GLOBENEWSWIRE
15 Apr 2024
Pulmocide exits OPERA with evidence of antifungal efficacy
Pulmocide exits OPERA with evidence of antifungal efficacy

15 Apr 2024

// Nick Paul Taylor FIERCE BIOTECH

https://www.fiercebiotech.com/biotech/pulmocide-exits-opera-phase-2-evidence-antifungal-safety-and-efficacy

Nick Paul Taylor FIERCE BIOTECH
15 Apr 2024

https://www.globenewswire.com//news-release/2023/10/16/2760577/0/en/Pulmocide-Announces-New-Clinical-Data-Confirming-Low-Potential-for-Drug-Drug-Interactions-with-Inhaled-Opelconazole.html

GLOBENEWSWIRE
16 Oct 2023

https://www.globenewswire.com/news-release/2023/06/08/2684591/0/en/Pulmocide-Announces-Expansion-of-Management-Team.html

GLOBENEWSWIRE
08 Jun 2023

https://www.globenewswire.com//news-release/2022/12/06/2568135/0/en/Pulmocide-Raises-52-Million-to-Fund-Additional-Late-Stage-Development-of-Opelconazole.html

GLOBENEWSWIRE
06 Dec 2022

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty